类器官
生物类器官、类器官分析及计算模型。连接研究原文、公司档案与当前公开已核验事件;保留来源和日期。
主题标签来自自动检索分类,用于找到相关材料;它不证明公司具有某项技术,也不等于研究已建立因果或临床效果。
研究与行业原文
A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布:Wed Nov 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Nov 05 2026 16:07:31 GMT+0000 (Coordinated Universal Time)
Cancer cells show highly heterogeneous and plastic states in glioblastoma, an incurable brain tumour 1-5 . However, how these malignant states arise and whether they follow defined cellular trajectories across tumours is
提速 60%:晶泰科技重磅论文揭示 AI+类器官如何重塑药物研发新范式
XtalPi official Chinese RSS · 行业原文收录 · 来源发布:Fri Sep 04 2026 01:29:23 GMT+0000 (Coordinated Universal Time) · 本站收录:Mon Sep 14 2026 05:56:48 GMT+0000 (Coordinated Universal Time)
药物研发有一个绕不开的困境:早期实验表现再好的分子,到了人体身上也可能失败。 AI让“找到看起来不错的分子”这件事越来越快。但 验证的难题反而被进一步放大 :我们能不能更早判断,它在真实疾病环境中是否真的有效? 围绕这一难题,2026 年 8 月,晶泰科技与孵化企业希格生科在《中国药事》上联合发表了一篇论文《类器官+人工智能在药物研发中的应用探讨》。 论文背景是双方合作开发的弥漫性胃癌候选药物 SIGX1094,这是全球首款获得“医药界
Systematic scRNA-seq screens profile neural organoid response to morphogens.
Europe PMC REST API · 学术索引收录 · 来源发布:Mon Dec 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Morphogens direct neuroepithelial fates toward discrete regional identities in vivo. Neural organoids provide models for studying neural regionalization through morphogen exposure; however, we lack a comprehensive survey
Cell tracking with accurate error prediction.
Europe PMC REST API · 学术索引收录 · 来源发布:Wed Oct 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 06:39:04 GMT+0000 (Coordinated Universal Time)
Cell tracking is an indispensable tool for studying development by time-lapse imaging. However, existing cell trackers cannot assign confidence to predicted tracks, which prohibits fully automated analysis without manual
Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology.
Europe PMC REST API · 学术索引收录 · 来源发布:Wed May 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 06:43:58 GMT+0000 (Coordinated Universal Time)
Organoids replicate tissue architecture and function and offer a unique opportunity to explore the impact of external perturbations in vitro. However, conducting large-scale screening procedures to investigate the effect
The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Mon Jan 06 2025 13:23:34 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagents, and benchtop ins
The Life Science business of Merck KGaA, Darmstadt, Germany, to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Tue Dec 17 2024 14:05:21 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potential to speed up drug developm
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Tue May 14 2024 12:51:39 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
HUB Organoids B.V. revolutionizes preclinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. San Antonio, TX — May 14 2024 — Frost & Sullivan recently r
HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Wed Jan 24 2024 17:36:01 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new Inte
Tumors in Space Investigates Microgravity’s Impact on Cancer Using Patient-Derived HUB Organoids
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Thu Nov 30 2023 09:42:03 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Utrecht, November 30, 2023 – HUB Organoids B.V. participates in the second Tumors in Space European Space Agency parabolic flight which investigates the effect of microgravity on gene expression to identify potential tar
HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Tue Jul 18 2023 01:00:54 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a significant milestone in its evolution. After years of successful operations as a found
HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology
HUB Organoids official news RSS · 行业原文收录 · 来源发布:Sat Mar 04 2023 13:34:09 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and HUB Organoids (HUB), the pioneer in the field of adult stem cell-der
当前公开已核验事件
当前没有符合条件的公开已核验事件。
有相关公开原文的公司
- 晶泰科技 · AI与模型数据 · 中国/美国
专题指南:从原文到判断
按任务比较模型,按证据追踪合作;每篇保留原始出处与更新日期。